

Innovating with purpose to lead where medicine is going

At J&J Innovative Medicine, we aspire to develop breakthrough treatments to transform the future of health, discovering new pathways and modalities to be in front of diseases and find cures. Inspired by patients, we apply rigorous science with compassion to confidently address the serious health problems of today and develop the potential medicines of tomorrow.



\$57B+

In 2024 sales¹



23

Consecutive years on pharma industry list on Fortune's World's Most Admired Companies²



70+

Projected novel therapies and product expansions by 2030*



\$13.5B

2024 R&D Investment³



Top 5

Ranked in the Access to Medicines Index in 2024⁴

Delivering 23 new medicines in the last decade and aiming to deliver up to 20 novel therapies and 50 product expansions by 2030.

Setting a new pace for discovery and delivery of transformational treatments by combining artificial intelligence, machine learning, real-world evidence and advanced computing with scientific expertise.

Above market 2024 results driven by double-digit growth across 11 different brands

Boldly pursuing the best partners in the global innovation ecosystem to advance scientific breakthroughs and solutions to help patients. -

Founded in 1886 in New Brunswick, New Jersey, by the 3 Johnson brothers; President and Chief Executive Officer: Joaquin Duato

¹https://s203.q4cdn.com/636242992/files/doc_financials/2024/q4/Earnings-Infographic-4Q2024.pdf

²<https://www.jnj.com/latest-news/johnson-johnson-named-a-2025-fortune-worlds-most-admired-company>

³https://s203.q4cdn.com/636242992/files/doc_financials/2024/q4/4Q24-Press-Release-with-attachments.pdf

⁴<https://accessmedicinefoundation.org/news/pharma-companies-still-not-maximising-their-potential-to-reach-more-patients-in-low-and-middle-income-countries>

* https://s203.q4cdn.com/972069832/files/doc_downloads/2023/12/enterprise-overview-presentation.pdf/risk-adjusted basis including filings and current year approvals